Seres Therapeutics returns to Q2 FY26 net income of 4.58 million; revenue rises to 736,000
MCRB•Pipeline update
SER-155 irEC investigator-sponsored trial showed 80% immunosuppressive-free clinical response at day 15; Seres weighed partnering while cutting facility costs.
Q2 FY26 results
Seres Therapeutics swung to net income of USD 4.6 million in Q2 2026 from a loss a year earlier, driven by a USD 25 million VOWST sale gain.
Revenue was USD 736,000, versus no revenue a year earlier.
Cash position and outlook
Cash and cash equivalents totaled USD 15.6 million at June 30; runway forecast through Q1 2027 including Nestlé milestone termination payments.
Expenses and operating loss
Research and development expense fell 29.36% to USD 9.1 million; general and administrative expense dropped 31.46% to USD 7.1 million.
Operating loss narrowed to USD 21.3 million from USD 24.9 million.
